HUTCHMED Financial Statements From 2010 to 2025
| HCM Stock | USD 14.68 0.25 1.73% |
Check HUTCHMED DRC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HUTCHMED DRC's main balance sheet or income statement drivers, such as , as well as many indicators such as . HUTCHMED financial statements analysis is a perfect complement when working with HUTCHMED DRC Valuation or Volatility modules.
Check out the analysis of HUTCHMED DRC Correlation against competitors. HUTCHMED DRC Company Profit Margin Analysis
HUTCHMED DRC's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current HUTCHMED DRC Profit Margin | 0.78 % |
Most of HUTCHMED DRC's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HUTCHMED DRC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, HUTCHMED DRC has a Profit Margin of 0.7753%. This is 106.92% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The profit margin for all United States stocks is 161.05% lower than that of the firm.
HUTCHMED DRC Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining HUTCHMED DRC's current stock value. Our valuation model uses many indicators to compare HUTCHMED DRC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across HUTCHMED DRC competition to find correlations between indicators driving HUTCHMED DRC's intrinsic value. More Info.HUTCHMED DRC is rated # 3 in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value HUTCHMED DRC by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About HUTCHMED DRC Financial Statements
HUTCHMED DRC investors utilize fundamental indicators, such as revenue or net income, to predict how HUTCHMED Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
HUTCHMED Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchmed China operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 2110 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of HUTCHMED DRC Correlation against competitors. To learn how to invest in HUTCHMED Stock, please use our How to Invest in HUTCHMED DRC guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HUTCHMED DRC. If investors know HUTCHMED will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HUTCHMED DRC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of HUTCHMED DRC is measured differently than its book value, which is the value of HUTCHMED that is recorded on the company's balance sheet. Investors also form their own opinion of HUTCHMED DRC's value that differs from its market value or its book value, called intrinsic value, which is HUTCHMED DRC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HUTCHMED DRC's market value can be influenced by many factors that don't directly affect HUTCHMED DRC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HUTCHMED DRC's value and its price as these two are different measures arrived at by different means. Investors typically determine if HUTCHMED DRC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HUTCHMED DRC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.